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ABSTRACT 1 
Purpose: To compare endocrine responses to intermittent vs continuous enteral 2 
nutrition provision during short-term bed rest.  3 
Methods: Twenty healthy men underwent 7 days of bed rest, during which they were 4 
randomized to receive enteral nutrition (47%E as carbohydrate,  34%E as fat, 16%E 5 
as protein and 3%E as fiber) in a continuous (CONTINUOUS; n=10; 24 hday-1 at a 6 
constant rate) or intermittent (INTERMITTENT; n=10; as 4 meals per day separated 7 
by 5 hours) pattern. Daily plasma samples were taken every morning to assess 8 
metabolite/hormone concentrations.  9 
Results: During bed rest, plasma leptin concentrations were elevated to a lesser 10 
extent with INTERMITTENT vs CONTINUOUS (iAUC: 0.42±0.38 vs 0.95±0.48 nmolL-11 
1, respectively; P=0.014) as were insulin concentrations (interaction effect, P<0.001) 12 
which reached a peak of 369±225 pmolL-1 in CONTINUOUS, compared to 94±38 13 
pmolL-1 in INTERMITTENT (P = 0.001). Changes in glucose infusion rate were 14 
positively correlated with changes in fasting plasma GLP-1 concentrations (r=0.44, 15 
P=0.049).  16 
Conclusion: Intermittent enteral nutrition attenuates the progressive rise in plasma 17 
leptin and insulinemia seen with continuous feeding during bed rest, suggesting that 18 
continuous feeding increases insulin requirements to maintain euglycemia. This raises 19 
the possibility that hepatic insulin sensitivity is impaired to a greater extent with 20 
continuous versus intermittent feeding during bed rest. To attenuate endocrine and 21 
metabolic changes with enteral feeding, an intermittent feeding strategy may therefore 22 
be preferable to continuous provision of nutrition. 23 
 24 
Abbreviations 25 
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GLP-1, glucagon-like peptide-1; 26 
HbA1c, glycated hemoglobin; 27 
RM, resting metabolic rate; 28 
iAUC, incremental area under the curve; 29 
SD, standard deviation; 30 
ANOVA, analysis of variance; 31 
GIR, glucose infusion rate 32 
 33 
INTRODUCTION 34 
Malnutrition during hospitalisation is a common occurrence [1] and is associated with 35 
poorer patient outcomes [2] delayed discharge times, and an increase in associated 36 
costs [3]. When nutritional requirements cannot be met by normal eating due to either 37 
lack of consciousness, swallowing difficulties, or lack of appetite, then enteral 38 
nutritional support is advised, particularly when oral intake is likely to be insufficient 39 
(<70% of requirements) for 3-7 days [4,5]. Enteral nutrition is preferred over parenteral 40 
nutrition due to lower infection risks [6] and because it represents a more 41 
“physiological” mode of nutrition delivery [4]. For example, nutrients in the 42 
gastrointestinal tract are responsible for the incretin effect; a phenomenon whereby 43 
the peptides glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic 44 
polypeptide (GIP) stimulate insulin secretion. Accordingly, intravenous glucose does 45 
not raise GLP-1 concentrations above basal [7], whereas both oral ingestion [7,8], and 46 
enteral nutrition (either gastric or jejunal delivery [9]) potently raise plasma 47 
postprandial GLP-1 concentrations above fasting values. Importantly, the incretin 48 
effect has a central role in metabolic control; responsible for the majority (up to 70%) 49 
of postprandial insulin secretion in healthy humans [10,11]. 50 
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Metabolic complications are common with nutritional therapy and the prevalence of 51 
insulin resistance in patients with enteral tube feeding is ~33% [12], which could be 52 
due to a number of factors including muscle disuse [13], injury/illness-associated 53 
stress [12] and/or the endocrine disruption due to enteral nutrition delivery pattern and 54 
mode [9,14]. In intensive care, it is most commonly recommended to provide enteral 55 
nutrition in a continuous pattern, rather than an intermittent pattern that better mimics 56 
feeding patterns in normal daily life [5,15]. There is little information on the role of 57 
enteral feeding patterns on endocrine and metabolic responses in vivo in humans. The 58 
decline in peripheral insulin sensitivity during bed rest with enteral nutrition appears to 59 
be independent of the pattern (intermittent vs continuous) of enteral nutrition delivery 60 
in humans [16]. However, it is unknown whether feeding pattern alters other aspects 61 
of metabolism or endocrine function. 62 
Alongside evidence that exogenous GLP-1 improves glycaemic control in healthy and 63 
critically ill humans [17-19], it has been suggested that endocrine alterations (including 64 
GLP-1) may be a key mechanism underlying the metabolic responses to differing 65 
delivery modes and patterns of enteral nutrition [9,14]. Alongside GLP-1, other peptide 66 
hormones, such as ghrelin, glucagon and leptin are also responsive to feeding, and 67 
all play important roles in glucose metabolism, insulin sensitivity and appetite 68 
regulation [21-25]. In the early phase of enteral feeding (first 4 hours), an intermittent 69 
pattern produces a divergent insulin and gut hormone response compared to a 70 
continuous pattern [26]. Non-randomized trials indicate that intermittent feeding over 71 
3 days suppresses appetite ratings and plasma ghrelin concentrations and raises 72 
plasma leptin and glucagon concentrations compared to placebo [27], whereas 73 
continuous feeding does not suppress appetite or alter plasma glucagon 74 
concentrations compared to placebo [28]. To date, however, there are no direct 75 
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comparisons of intermittent vs continuous enteral tube feeding on peptide responses 76 
over a time-period when enteral nutrition is typically advised (i.e. ~5-7 days).  77 
An opportunity arose to address whether enteral feeding pattern alters endocrine 78 
responses during 7 days of bed rest by making use of plasma samples collected as 79 
part of a wider project examining muscle metabolism and mitochondrial capacity 80 
[16,29]. Blood samples and appetite ratings were taken each morning throughout 7 81 
days of bed rest with enteral nutrition delivered in an intermittent vs continuous pattern. 82 
Accordingly, the aim of this study was to assess the effects of an intermittent pattern 83 
of enteral nutrition during 7 days of bed rest on endocrine (insulin, glucagon, GLP-1, 84 
ghrelin, and leptin) responses, compared to current standard practice of continuous 85 
enteral nutrition. We also aimed to characterise the relationship between endocrine 86 
responses, insulin sensitivity, and appetite. We hypothesised that intermittent feeding 87 
may increase plasma glucagon and ghrelin concentrations alongside increases in 88 
appetite ratings, whilst decreasing insulin concentrations, when compared to 89 
continuous feeding. 90 
 91 
MATERIALS AND METHODS 92 
Study design 93 
The data presented in the current manuscript are part of a larger study on muscle 94 
metabolic responses to enteral feeding patterns during bedrest [16]. Where data have 95 
previously been reported, this is clearly stated and cited. All endocrine data presented 96 
in this manuscript have not been reported previously. After screening, twenty 97 
participants completed baseline testing and began a control period comprising 7 days 98 
of standardised nutrition. On day 7 of the control period, participants underwent body 99 
composition testing and a hyperinsulinemic-euglycemic clamp to determine whole-100 
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body insulin sensitivity. On the same evening, participants arrived at the University for 101 
insertion of a nasogastric tube and remained at the University overnight. The following 102 
morning at 08:00, a 7-day period of bed rest began. During this period, participants 103 
were randomized to receive enteral nutrition in either an intermittent (INTERMITTENT; 104 
n = 10; 4 meals per day) or continuous (CONTINUOUS; n = 10; 24 hday-1 at a constant 105 
rate) pattern. After seven days of bed rest, the hyperinsulinemic-euglycemic clamp 106 
was repeated to determine changes in whole-body insulin sensitivity. 107 
In order to characterise the acute responses with temporal resolution, one additional 108 
participant with characteristics representative of study population (age: 28 years; 109 
stature: 1.86 m; body mass: 93 kg) completed two, 24-hour periods of bed rest with 110 
nasogastric feeding in either an intermittent (4 meals per day) or continuous pattern, 111 
with a 7-day washout period. Blood was sampled hourly to characterise the initial 112 
diurnal responses to the protocol. 113 
 114 
Participants 115 
The present study recruited young healthy men (age range for recruitment: 18-35 116 
years), on the basis that this would allow for an understanding of the effects of feeding 117 
pattern per se, without the potential confounding of interactions with injuries/illnesses. 118 
Participant’s characteristics are presented in Table 1 [as previously reported [16]]. All 119 
participants were informed of the nature and risks of the experiment prior to taking part 120 
before informed, written consent was obtained. Prior to participation, participants also 121 
completed a general health questionnaire and medical screening to determine their 122 
eligibility to participate. Exclusion criteria included: a body mass index below 18.5 or 123 
above 30 kgm-2; a family history of deep vein thrombosis, type 2 diabetes (defined by 124 
HbA1c >7.0%); any back, knee or shoulder complaints that could be contraindicative 125 
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of bed rest; and participation (in the 6 months prior to the study) in resistance-type 126 
exercise training. During screening, a blood sample was obtained in the fasted state 127 
and resting metabolic rate was determined using a ventilated hood. The current study 128 
was approved by the Medical Ethical Committee of Maastricht University Medical 129 
Centre+ (registration number MEC 15-3-035) in accordance with the Declaration of 130 
Helsinki. 131 
 132 
Bed rest 133 
Participants underwent a 7-day period of strict bed rest to mimic the effects of 134 
hospitalization. On day 1 of bed rest, at 08:00, participants began the bed rest 135 
procedure during which they were not permitted to leave the bed for 7 days. 136 
Participants were woken at 07:30 and lights were switched off at 23:30 daily. During 137 
daytime, participants were permitted to use a pillow and slight elevation of the bed in 138 
order to perform daily activities. Washing and all sanitary activities were performed in 139 
bed. Participants were constantly monitored by members of the research team. 140 
 141 
Nutritional intake 142 
During screening, resting metabolic rate (RMR) was determined via indirect 143 
calorimetry using an open-circuit ventilated hood system (Omnical, Maastricht 144 
University, Maastricht, the Netherlands; [30]). During the 7-day control period prior to 145 
bed rest, and during the bed rest period, all nutrition was provided by the research 146 
team and dietary intake was standardised to achieve energy balance based on RMR 147 
multiplied by either 1.60 (control period prior to bed res) or 1.35 (for bed rest). The 148 
macronutrient composition of the diet was identical during both the control period prior 149 
to bed rest, and the bed rest period. 150 
Page 9 of 31 
During bed rest, enteral nutrition was provided via a nasogastric tube (Flocare© PUR 151 
tube Enlock, Ch8, 110 cm, Nutricia Advanced Medical Nutrition, the Netherlands). 152 
Correct placement of the tube in the stomach was confirmed by pH assessment 153 
immediately following insertion and on every morning during bed rest. A standard 154 
enteral nutrition product (Nutrison Multi Fibre, Nutricia Advanced Medical Nutrition) 155 
was employed, providing carbohydrates (47% energy) fat (34% energy), protein (16% 156 
energy) and fiber (3% energy). During INTERMITTENT, participants received nutrition 157 
in four daily boluses, administered at 08:00 (30% of daily energy intake; ~720 kcal 158 
over 30 min), 13:00 (30% of daily energy intake; ~720 kcal over 30 min), 18:00 (30% 159 
of daily energy intake; ~720 kcal over 30 min) and 23:00 (10% of daily energy intake; 160 
~240 kcal over 10 min) at a rate of 25 mLmin-1, with the first meal administered on the 161 
morning of the first day of bed rest. During CONTINUOUS, participants received 162 
nutrition in a continuous pattern via a Flocare© Infinity enteral feeding pump (Nutricia 163 
Advanced Medical Nutrition) at a constant rate (~100 mLh-1, depending on energy 164 
requirements, equating to a mean intake of ~100 kcalh-1). Continuous feeding began 165 
at 00:00 on the evening before bed rest and ended at 00:00 on the evening of day 7 166 
to allow for the final measures to be determined in a fasted state. Nasogastric tubes 167 
were removed at 00:00 on the evening of day 7 in both groups. 168 
 169 
Body composition 170 
Height was determined using a stadiometer, and body mass was determined with 171 
participants wearing minimal clothing. Body composition was determined by dual-172 
energy x-ray absorptiometry (DXA; Hologic, Discovery A, QDR Series, Bradford, MA, 173 
USA) The software package Apex v 4.0.2 was used to determine whole body fat mass. 174 
 175 
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Hyperinsulinemic-euglycemic clamp 176 
Whole-body insulin sensitivity was assessed by a hyperinsulinemic-euglycemic clamp 177 
on the days immediately before and after bed rest as previously described [13]. Briefly, 178 
an intravenous cannula was inserted retrogradely into a dorsal hand vein, with the 179 
hand kept in a heated box (60C) for sampling of arterialised blood. In the contralateral 180 
arm, an intravenous cannula was inserted into an antecubital vein for infusion of 20% 181 
glucose (Baxter B.V., Utrecht, Netherlands) and insulin (40 mUm-2min-1; Novorapid, 182 
Novo Nordisk Farma, Alphen aan den Rijn, the Netherlands). Blood was sampled 183 
every 5 min throughout the 2.5 h clamp to determine glucose concentration (ABL800 184 
FLEX; Radiometer Medical, Brønshøj, Denmark). Glucose infusion rate (GIR) was 185 
altered in order to maintain euglycemia at 5.0 mmolL-1, and average GIR of the last 186 
30 min was used as a measure of peripheral insulin sensitivity. 187 
 188 
Blood sampling and analysis 189 
Blood was sampled via venepuncture prior to the control period, and then at 08:00 on 190 
each morning of bed rest. Since the CONTINUOUS group were constantly in a fed 191 
state, all blood samples during bed rest were taken in a “postprandial” state in this 192 
group, vs a fasted state in the INTERMITTENT group. In order to ascertain an effect 193 
of feeding pattern independent from feeding status, a final blood sample was collected 194 
at 08:00 (in the fasted state for both groups) on the day after bed rest (day 8) prior to 195 
the hyperinsulinemic-euglycemic clamp. Samples were collected in EDTA-coated 196 
tubes and immediately centrifuged at 1000g for 10 min at 4C. Plasma was divided 197 
into aliquots, snap frozen in liquid nitrogen and stored at -80C until subsequent 198 
determination of glucose (GLUC3, reference 05168791 190, Roche; detection limits; 199 
0.11-41.6 mmol·L-1), glycated haemoglobin (determined in 4 mL venous blood by high-200 
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performance liquid chromatography; Bio-Rad Diamat, Munich, Germany) insulin 201 
(Immunologic, reference 12017547 122, Roche; detection limits; 1.39-6945 pmol·L-1), 202 
GLP-1Total (Epitope Diagnostics Inc. CA, USA; detection limits; 0.6-54 pmol·L-1) ghrelin 203 
(EMD Millipore, Germany; detection limits; 50-5000 pg·mL-1) glucagon (Mercodia AB, 204 
Sweden; detection limits; 0.024-100000 pmol·L-1) leptin (Mercodia AB, Sweden). Intra- 205 
and inter-assay co-efficients of variation were all <8%. 206 
 207 
Appetite ratings 208 
Appetite ratings were determined using 100 mm visual analogue scales [31] with 209 
descriptors anchored at each end describing the extremes (e.g. “I am not hungry at 210 
all” versus “I have never been more hungry”). Participants rated their appetite by 211 
placing a vertical mark across each line on paper, and participants were not permitted 212 
to refer to their previous ratings when completing the scales. Scales were analyzed by 213 
measuring the horizontal distance from the left-had anchor to the point marked by the 214 
participant. 215 
 216 
Statistics 217 
The sample size for the study was based on the primary outcome of glucose infusion 218 
rate as reported in the parent manuscript [16]. However, this sample size should also 219 
be sufficient to detect meaningful differences in endocrine responses based on data 220 
reported by Stoll et al. [14], whereby INTERMITTENT resulted in a plasma GLP-1 221 
concentrations of 43±11 pmolL-1, compared to 32±3 pmolL-1 with CONTINUOUS. 222 
Using this effect size (d=1.36), ten participants in each group should provide a power 223 
of 0.82 with a two-tailed -level of 0.05 in a between-group design [32]. 224 
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Data are expressed as mean±SD in text and tables and mean±95%CI in figures. Data 225 
were analyzed using Prism v7 (GraphPad Software, San Diego, CA) and log-226 
transformed if appropriate, prior to analysis (determined by Shapiro-Wilk normality 227 
test). Baseline differences between groups were assessed using independent t-test. 228 
Changes over time were assessed by repeated measures ANOVA, with time (days 0-229 
7 or pre- vs post-bed rest) as the within-subjects factor and group (INTERMITTENT 230 
vs CONTINUOUS) as the between-subjects factor. The incremental area under the 231 
curve (iAUC) for plasma peptide concentrations over time (above baseline for GLP-1, 232 
glucagon and leptin; below baseline for ghrelin), was calculated using the trapezoidal 233 
method to use as a summary statistic. Between group differences (INTERMITTENT 234 
vs CONTINUOUS) in iAUC, and pre- to post-bed rest change in fasting variables 235 
(glucose infusion rate, plasma glucose and hormone concentrations) were analyzed 236 
by independent t-tests. Relationships between variables were analyzed by Pearson 237 
correlation coefficients when normally distributed, or Spearman correlation coefficients 238 
when non-normally distributed (determined by Shapiro-Wilk normality test). All P 239 
values were corrected for multiple comparisons using the Holm-Sidak adjustment. A 240 
P value of 0.05 was used to determine statistical significance. 241 
 242 
RESULTS 243 
Acute endocrine responses to modulation of 24-h enteral nutrition pattern 244 
The acute (24-h) endocrine responses to intermittent vs continuous enteral feeding 245 
are displayed in Figure 1, using data from an additional participant (n = 1). Plasma 246 
glucose concentrations followed a relatively similar pattern with intermittent vs 247 
continuous feeding (Figure 1A), whereas plasma insulin concentrations varied 248 
markedly more with intermittent, compared to continuous feeding (Figure 1B), 249 
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increasing ~9-fold following each main bolus feed. At the 24 h timepoint, plasma 250 
insulin concentrations were comparable between intermittent and continuous feeding 251 
patterns. Plasma GLP-1 concentrations increased >4-fold within 1 h after each main 252 
meal during INTERMITTENT, returning to basal concentrations following the overnight 253 
period (Figure 1C). During CONTINUOUS, plasma GLP-1 concentrations displayed 254 
less variability (Figure 1C). Similarly, plasma glucagon concentrations (Figure 1D) 255 
fluctuated more widely with INTERMITTENT vs CONTINUOUS, increasing >7-fold 256 
from basal with the first meal during INTERMITTENT, whereas during CONTINUOUS 257 
plasma glucagon concentrations did not rise more than 2-fold above basal values at 258 
any time point. By 24 h, plasma glucagon concentrations were comparable to baseline 259 
values during both INTERMITTENT and CONTINUOUS. Plasma ghrelin 260 
concentrations (Figure 1E) decreased with feeding during INTERMITTENT, from 261 
~640 to 312 pmolL-1, whereas plasma ghrelin concentrations did not decrease below 262 
522 pmolL-1 at any time point during CONTINUOUS (Figure 1E). Plasma leptin 263 
concentrations however, remained stable over 24 h and did not differ between 264 
INTERMITTENT vs CONTINUOUS feeding (Figure 1F). 265 
 266 
Plasma glucose, insulin and glucagon responses during 7 days of bed rest 267 
At baseline, no differences were detected between INTERMITTENT vs 268 
CONTINUOUS in plasma glucose, insulin, GLP-1, glucagon, ghrelin, or leptin 269 
concentrations, nor insulin-to-glucagon ratio (all P > 0.05; Figures 2 and 3). Whilst a 270 
modest difference in plasma glucose concentrations was observed after day 1 of bed 271 
rest with NTERMITTENT vs CONTINUOUS, (interaction effect, P < 0.001) thereafter, 272 
plasma glucose concentrations did not differ between conditions for the remainder of 273 
the 7 days of bed rest (Figure 2A). 274 
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Plasma insulin concentrations did not differ between INTERMITTENT vs 275 
CONTINUOUS for the first day of bed rest. Thereafter, plasma insulin concentrations 276 
remained stable in INTERMITTENT, but began to rise in CONTINUOUS (interaction 277 
effect, P < 0.001; Figure 2B), reaching peak concentrations of 94±38 pmolL-1 in 278 
INTERMITTENT, compared to 369±225 pmolL-1 in CONTINUOUS (P = 0.001). 279 
Plasma glucagon concentrations began to decrease during the first two days of bed 280 
rest in both groups (time effect, P = 0.002), but towards day 7 of bedrest, plasma 281 
glucagon concentrations began to rise in the INTERMITTENT group only (interaction 282 
effect, P = 0.042; Figure 2C). 283 
The plasma insulin-to-glucagon ratio remained stable during bed rest with 284 
INTERMITTENT, but increased with CONTINUOUS (interaction effect, P < 0.001) 285 
such that by days 6 and 7, the plasma insulin-to-glucagon ratio was lower with 286 
INTERMITTENT vs CONTINUOUS (Figure 2D; P < 0.05).  287 
 288 
Plasma GLP-1, ghrelin and leptin responses during 7 days of bed rest 289 
Plasma GLP-1 concentrations (Figure 3A) were not altered during bed rest compared 290 
to baseline values (time effect, P = 0.93). The delivery pattern of enteral nutrition, 291 
however, did alter the plasma GLP-1 response over time (interaction effect, P = 0.024), 292 
although following adjustment for multiple comparisons, none of the differences 293 
between feeding patterns at any time point remained significant (Figure 3A).  294 
Compared to baseline, plasma ghrelin concentrations decreased during bed rest (time 295 
effect, P < 0.001), to a similar extent in INTERMITTENT vs CONTINUOUS groups 296 
(interaction effect, P = 0.79; Figure 3B). 297 
Plasma leptin concentrations increased during bed rest, compared to baseline (time 298 
effect, P < 0.001) but to a lesser extent in the INTERMITTENT vs CONTINUOUS 299 
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group (interaction effect, P = 0.001; Figure 3C). Moreover, the leptin iAUC was lower 300 
with INTERMITTENT vs CONTINUOUS (0.95±0.48 vs 0.42±0.38 nmolL-1, 301 
respectively; P = 0.014). 302 
 303 
Appetite ratings during bed rest 304 
During bed rest, appetite ratings were higher in the INTERMITTENT vs CONTINUOUS 305 
group (group effect, P = 0.01). Following adjustment for multiple comparisons, the 306 
INTERMITTENT group reported higher appetite ratings at both 0800 and 1800 h on 307 
day 7 only (Table 2). Moreover, appetite ratings on day 7 positively correlated with 308 
plasma ghrelin concentrations sampled at the same time point (Figure 4). Appetite 309 
ratings did not correlate with either plasma glucagon or leptin concentrations (both P 310 
> 0.05). 311 
 312 
Changes in fasting plasma glucose and regulatory hormones following 313 
bedrest 314 
Fasting plasma GLP-1 concentrations decreased from pre-to-post 7 days of bed rest 315 
with INTERMITTENT versus CONTINUOUS (P = 0.024; Figure 5D). In contrast, 316 
fasting glucagon, ghrelin and leptin concentrations were unaltered by enteral feeding 317 
pattern (all P > 0.05 for; Figures 5A, 5B, 5C, 5E and 5F). 318 
Insulin sensitivity 319 
As previously reported, GIR declined by ~42% following 7 days of bed rest, 320 
independent of feeding pattern (data from both groups pooled in the present 321 
manuscript; Figure 6A [16]). However, the change in GIR positively correlated with 322 
the change in log plasma GLP-1 concentrations (Figure 6B), but not the change in 323 
glucagon, ghrelin or leptin concentrations (all P > 0.05). 324 
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 325 
DISCUSSION 326 
The present study demonstrates that intermittent enteral nutrition attenuates the 327 
increase in post-absorptive plasma insulin and leptin concentrations but has little 328 
impact on plasma glucose, GLP-1 and ghrelin concentrations, when compared to 329 
continuous enteral nutrition during 7 days of bed rest.  330 
Enteral nutrition is advised when nutritional requirements during hospitalisation are 331 
unlikely to be met by oral ingestion for >5-7 days [4,5]. Enteral nutrition is generally 332 
provided in a continuous pattern (50-100 mLh-1 over 12-24 hday-1), possibly due to 333 
logistics and time commitments of clinical staff, although an intermittent feeding 334 
pattern mimicking habitual dietary feeding, is occasionally used [4]. The effect of 335 
dietary feeding pattern on insulin sensitivity and endocrine responses in humans are 336 
not well characterised. This is the first study to demonstrate that the nutrition delivery 337 
pattern modulates endocrine responses to enteral nutrition in humans in vivo, during 338 
a time period when enteral nutrition is advised (e.g. >5 days). Our data also 339 
demonstrate that intermittent feeding lowers fasting plasma glucose and GLP-1 340 
concentrations compared to continuous feeding, and the changes in fasting GLP-1 are 341 
associated with changes in peripheral insulin sensitivity during bed rest. 342 
In addition to peripheral insulin sensitivity, hepatic insulin sensitivity is a major 343 
contributor to glucose control [33]. Hepatic glucose production is primarily regulated 344 
by the insulin-to-glucagon ratio [34]. Here, we demonstrate that insulin concentrations 345 
required to maintain euglycemia progressively increase across 7 days of bed rest with 346 
continuous enteral feeding, whereas intermittent feeding prevented this increase in 347 
insulinemia. Whilst the continuous group would have a continuous exogenous glucose 348 
appearance at a rate of ~0.2 gmin-1, this was not sufficient to raise insulinemia until 349 
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at least 48 hours of bed rest, with nutrition provided to meet energy requirements. This 350 
suggests that the increase in insulinemia is due to the development of insulin 351 
resistance, rather than a physiological response to continuous exogenous 352 
carbohydrate appearance. When combined with our previously reported observations 353 
that feeding pattern does not alter the decline in peripheral insulin sensitivity or muscle 354 
mitochondrial function during bed rest [16,29], and also with evidence that hepatic 355 
insulin sensitivity plays a more important role in glucose control at low insulin 356 
concentrations that at high insulin concentrations [33], this suggests that hepatic 357 
insulin sensitivity was declining with continuous versus intermittent feeding. This is in 358 
line with prior observations that 7 days of head down-tilt bed rest with nutritional intake 359 
as 3 meals per day, results in decreased peripheral insulin sensitivity, without a decline 360 
in hepatic insulin sensitivity in men [35]. Interestingly, women showed decreases in 361 
both peripheral and hepatic insulin sensitivity following bed rest [35]. Combined with 362 
our data, this suggests that maintaining a degree of fasting between meals can prevent 363 
hepatic insulin resistance during bed rest in men, but more work is required to 364 
understand if feeding pattern can alter hepatic insulin sensitivity during bed rest in 365 
women. Furthermore, our observations require confirmation with the addition of stable-366 
isotope methods to euglycemic-hyperinsulinemic clamps in order to definitively 367 
establish whether hepatic insulin sensitivity is altered by enteral feeding pattern during 368 
bed rest. 369 
GLP-1 is a gut hormone with a central role in postprandial metabolism [36] and is 370 
secreted in response nutrients in the gastrointestinal tract [37,38]. The present data 371 
demonstrate that continuous enteral nutrition delivered at a rate of 100 kcalh-1 is 372 
insufficient to increase GLP-1 concentrations above those seen in a fasted state. 373 
However, following 7 days of bed rest, an intermittent feeding pattern lowered fasting 374 
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GLP-1 concentrations compared to a continuous feeding pattern. Furthermore, 375 
individuals demonstrating the greatest decline in fasting GLP-1 concentrations also 376 
demonstrated the greatest decline in glucose infusion rate during a hyperinsulinemic-377 
euglycemic clamp. When considered alongside evidence that exogenous GLP-1 378 
improves glucose homeostasis in ICU patients [17], and may enhance glucose 379 
disposal in humans [18,19] (although not under all conditions [39,40]), these data 380 
suggest that endogenous GLP-1 plays a role in metabolic control during bed rest. As 381 
direct effects of GLP-1 on peripheral insulin sensitivity are unclear, the mechanism(s) 382 
by which GLP-1 may contribute to metabolic control are thought to also include 383 
microvascular recruitment and glucose-stimulated insulin secretion [36]. Whilst enteral 384 
feeding pattern does not modulate the decline in peripheral insulin sensitivity during 385 
bed rest [16], other strategies that increase endogenous GLP-1 concentrations, such 386 
as enteral delivery mode [9] and/or nutrient composition [38,41,42], warrant exploring 387 
as potential approaches to preserve GLP1 concentrations during bed rest. 388 
Leptin is a peptide hormone primarily derived from adipose tissue which is mostly 389 
known for its role in suppressing appetite, but can also increase insulin sensitivity [22], 390 
and has been shown to increase during bed rest [43]. Since leptin is thought to be 391 
mostly regulated by chronic changes in energy balance, it is important to note that 392 
participants in the present study were fed to maintain energy balance, confirmed by 393 
the stable fat mass (within 0.1 kg) previously reported [16]. Here, we demonstrate that 394 
intermittent feeding lessens the increase plasma leptin concentration seen during bed 395 
rest with continuous feeding. This provides the first evidence that feeding pattern can 396 
modulate the leptin response to bed rest, independent from energy balance. Since 397 
prolonged insulinemia is thought to stimulate increased leptin secretion [44,45], the 398 
progressive increase in insulinemia seen with continuous vs intermittent feeding may 399 
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explain this increase in leptin concentrations. If a higher leptin response is desirable, 400 
then a continuous feeding pattern could be a strategy to ensure high leptin 401 
concentrations independent from changes in energy balance. 402 
Ghrelin is primarily secreted from the gut and is currently the only known gut hormone 403 
to stimulate appetite. It has previously been reported that patients in the intensive care 404 
unit (ICU) display ~50% lower plasma ghrelin concentrations than age- and BMI-405 
matched healthy controls [46]. As the present study was conducted on healthy 406 
participants, this suggests that reductions in ghrelin concentrations that have 407 
previously been reported in the ICU might be a result of physical inactivity per se or 408 
changes in feeding mode, rather than illness. It remains to be established whether the 409 
reduction in plasma ghrelin concentrations is a direct result of bed rest, naso-gastric 410 
feeding, or an interaction between physical inactivity and naso-gastric feeding. 411 
Changes in ghrelin concentrations are likely to play a role in appetite regulation during 412 
bed rest, as demonstrated by both the positive relationship between appetite and 413 
ghrelin concentrations in the present study. This is in line with the positive relationship 414 
observed between plasma ghrelin concentrations and ad libitum food intake in ICU 415 
patients [46]. Since malnutrition is prevalent during and following periods in intensive 416 
care, strategies that reduce ghrelin concentrations should be considered with caution. 417 
It should also be noted that blood samples and appetite ratings measured during bed 418 
rest were taken in in the fasted state for the INTERMITTENT group, compared with 419 
constant nutrition in the CONTINUOUS group. Nevertheless, the differences in 420 
insulinemia and leptin were progressive, and not apparent within the first 24 h of 421 
continuous feeding. This suggests that these responses are a true reflection of the 422 
interaction between feeding pattern and bed rest, rather than an artefact of the 423 
sampling time point. A further consideration is that we recruited young, healthy men. 424 
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The generalisability of these findings to clinical nutrition and to women is, therefore, 425 
somewhat limited. Nevertheless, by studying healthy people, the present findings are 426 
able to isolate the effects of enteral feeding pattern independent from the diverse 427 
impact of disease states and injuries seen in clinical settings.  428 
In conclusion, these data demonstrate that enteral feeding pattern alters the endocrine 429 
response to bed rest in vivo in humans. Intermittent enteral nutrition attenuates the 430 
increase in plasma insulin and leptin concentrations along with the decline in plasma 431 
glucagon concentrations during 7 days of bed rest, when compared to a continuous 432 
feeding pattern. The increase in insulinemia in the absence of differences in peripheral 433 
insulin sensitivity, suggests that hepatic insulin sensitivity may be compromised to a 434 
greater extent with continuous feeding. If a clinical aim is to attenuate endocrine and 435 
metabolic changes seen with enteral feeding during bed rest, then an intermittent 436 
feeding pattern may be preferable over continuous delivery of enteral nutrition. 437 
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TABLES 628 
 629 
Table 1. Participant characteristics 630 
 631 
INTERMITTENT, intermittent enteral nutrition pattern; CONTINUOUS, continuous 632 
enteral nutrition pattern. Data previously reported [16]. HbA1c, glycated haemoglobin. 633 
 634 
  635 
 INTERMITTENT 
(n = 10) 
CONTINUOUS 
(n = 10) 
Age (y) 27 ± 4 24 ± 4 
Stature (m) 1.81 ± 0.09 1.79 ± 0.08 
Body mass (kg) 77.5 ± 16.2 77.3 ± 16.1 
Body mass index (kgm-2) 23.5 ± 4.0 24.0 ± 3.2 
HbA1c (%) 5.2 ± 0.3 5.2 ± 0.5 
Body fat (%) 22.9 ± 5.9 22.3 ± 3.8 
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Table 2. Appetite ratings during 7 days of bedrest with enteral nutrition 636 
provided in either an intermittent or continuous pattern. 637 
 638 
INTERMITTENT, intermittent enteral nutrition pattern; CONTINUOUS, continuous 639 
enteral nutrition pattern. 640 
  641 
Day Time 
Appetite rating (mm) INTERMITTENT vs 
CONTINUOUS 
Adjusted P value 
INTERMITTENT 
(n = 10) 
CONTINUOUS 
(n = 10) 
Day 1 
0800 h 39 ± 24 18 ± 14 0.162 
1800 h 38 ± 24 23 ± 18 0.783 
Day 4 
0800 h 39 ± 22 21 ± 18 0.376 
1800 h 40 ± 22 19 ± 14 0.115 
Day 7 
0800 h 41 ± 16 18 ± 15 0.029 
1800 h 46 ± 21 16 ± 14 0.009 
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FIGURE CAPTIONS 642 
Figure 1. Plasma glucose (A), insulin (B), GLP-1 (C), glucagon (D), ghrelin (E), and 643 
leptin (F) concentrations during 24 hours of bed rest in a representative participant (n 644 
= 1), with enteral nutrition provided in either an intermittent (INTERMITTENT) or 645 
continuous (CONTINUOUS) pattern. Dashed vertical lines indicate when nutrition was 646 
provided in the intermittent condition. GLP-1, glucagon-like peptide-1. 647 
 648 
Figure 2. Plasma concentrations of glucose (A), insulin (B), glucagon (C), and the 649 
insulin-to-glucagon ratio (D) before (day 0) and during 7-days of bed rest, and with 650 
enteral nutrition provided in either an intermittent (INTERMITTENT; n = 10) or 651 
continuous (CONTINUOUS; n = 10) pattern. Data are means ± 95%CI. *difference 652 
between INTERMITTENT and CONTINUOUS, P < 0.05. 653 
 654 
Figure 3. Plasma concentrations of GLP-1 (A; glucagon-like peptide-1), ghrelin (B), 655 
and leptin (C) concentrations before (day 0) and during 7-days of bed rest, and with 656 
enteral nutrition provided in either an intermittent (INTERMITTENT; n = 10) or 657 
continuous (CONTINUOUS; n = 10) pattern. Data are presented as group means ± 658 
95%CI. *p < 0.05 for INTERMITTENT vs CONTINUOUS. 659 
 660 
Figure 4. Relationship between plasma ghrelin concentration and appetite ratings 661 
during day 7 of bed rest conducted with enteral nutrition provided in either an 662 
intermittent (INTERMITTENT) or continuous (CONTINUOUS) pattern. 663 
 664 
Figure 5. Change in fasting plasma glucose (A) insulin (B), glucagon (C), GLP-1 (D), 665 
ghrelin (E) and leptin (F) concentrations after 7 days of bed rest with enteral nutrition 666 
provided in either an intermittent (INTERMITTENT) or continuous (CONTINUOUS) 667 
pattern. GLP-1, glucagon-like peptide-1. Individual data are presented (n = 10 per 668 
group) alongside group means ± 95%CI. 669 
 670 
Figure 6. Glucose infusion rate during a hyper-insulinemic, euglycemic clamp before 671 
(PRE) and after (POST) 7 days bed rest with enteral nutrition (A), as previously 672 
reported [16]. Relationship between the change in fasting plasma GLP-1 concentration 673 
and glucose infusion rate after 7 days of bed rest conducted with enteral nutrition 674 
provided in either an intermittent (INTERMITTENT) or continuous (CONTINUOUS) 675 
pattern (B). 676 
 677 
